Expertise in
72
conditions

Dr. Haifaa Abdulhaq

Hematology | Oncology
Community Medical Oncology Specialists
785 N Medical Center Dr W Ste 203, 
Clovis, CA 
Offers Telehealth
Expertise in
72
conditions
Community Medical Oncology Specialists
785 N Medical Center Dr W Ste 203, 
Clovis, CA 

Overview

Haifaa Abdulhaq is a Hematologist and an Oncologist in Clovis, California. Dr. Abdulhaq is highly rated in 72 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Tissue Biopsy.

Her clinical research consists of co-authoring 19 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in CA

Hospital Affiliations

Community Regional Medical Center
Saint Agnes Medical Center
Clovis Community Medical Center
Kaweah Health Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Community Medical Oncology Specialists
785 N Medical Center Dr W Ste 203, Clovis, CA 93611
Other Locations
University Oncology Associates Inc.
2335 E Kashian Ln Ste 301, Fresno, CA 93701

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug, Procedure
Study Drugs: Cytarabine, Daunorubicin, Uproleselan
Study Phase: Phase 2/Phase 3
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2025
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin, Daunorubicin, Cytarabine
Study Phase: Phase 2
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Drug
Study Drugs: Alvocidib, Cytarabine
Study Phase: Phase 2
A Phase III, Randomized, Double-blind Study of Chemotherapy With Daunorubicin or Idarubicin and Cytarabine for Induction and Intermediate Dose Cytarabine for Consolidation Plus Midostaurin (PKC412) or Chemotherapy Plus Placebo in Newly Diagnosed Patients With FLT-3 Mutation Negative Acute Myeloid Leukemia (AML)
A Phase III, Randomized, Double-blind Study of Chemotherapy With Daunorubicin or Idarubicin and Cytarabine for Induction and Intermediate Dose Cytarabine for Consolidation Plus Midostaurin (PKC412) or Chemotherapy Plus Placebo in Newly Diagnosed Patients With FLT-3 Mutation Negative Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: August 21, 2023
Intervention Type: Drug
Study Drug: Midostaurin
Study Phase: Phase 3
View 6 Less Clinical Trials

19 Total Publications

What to know about rare B-cell malignancies in 2025.
What to know about rare B-cell malignancies in 2025.
Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025
Similar Doctors
Expertise in
39
conditions
Dr. Dina Ibrahim
Hematology | Oncology
Expertise in
39
conditions
Dr. Dina Ibrahim
Hematology | Oncology

Jeffrey K Shinoda Pharm D Inc

6121 N Thesta St Ste 204, 
Fresno, CA 
 (5.6 miles away)
559-554-2100
Languages Spoken:
English
See accepted insurances

Dina Ibrahim is a Hematologist and an Oncologist in Fresno, California. Dr. Ibrahim is highly rated in 39 conditions, according to our data. Her top areas of expertise are Paget Disease of the Breast, Inflammatory Breast Cancer, Angiosarcoma, and Breast Cancer.

Expertise in
35
conditions
Dr. Muhammad Alam
Hematology | Oncology
Expertise in
35
conditions
Dr. Muhammad Alam
Hematology | Oncology

Jeffrey K Shinoda Pharm D Inc

6121 N Thesta St Ste 204, 
Fresno, CA 
 (5.6 miles away)
559-438-7390
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Muhammad Alam is a Hematologist and an Oncologist in Fresno, California. Dr. Alam is highly rated in 35 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Small Cell Lung Cancer (SCLC).

Expertise in
56
conditions
Dr. Amitoj Gill
Hematology | Oncology
Expertise in
56
conditions
Dr. Amitoj Gill
Hematology | Oncology

Sequoia Regional Cancer Center

4945 W Cypress Ave Ste C, 
Visalia, CA 
 (40.6 miles away)
559-624-3000
Experience:
18+ years
Languages Spoken:
English
See accepted insurances

Amitoj Gill is a Hematologist and an Oncologist in Visalia, California. Dr. Gill has been practicing medicine for over 18 years is highly rated in 56 conditions, according to our data. His top areas of expertise are Childhood Iron Deficiency Anemia, Lung Cancer, Iron Deficiency Anemia, and Pleuropulmonary Blastoma.

Frequently Asked Questions about Dr. Haifaa Abdulhaq

How do I make an appointment with Dr. Haifaa Abdulhaq?

You can book an appointment with Dr. Haifaa Abdulhaq by calling their office at 559-387-1900. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Haifaa Abdulhaq a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Haifaa Abdulhaq is classified as an Distinguished expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Haifaa Abdulhaq specialize in?

While Dr. Haifaa Abdulhaq is a Hematology, they have specific expertise in Non-Hodgkin Lymphoma, Multiple Myeloma, and Diffuse Large B-Cell Lymphoma (DLBCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Haifaa Abdulhaq participate in research or clinical trials?

Yes. Dr. Haifaa Abdulhaq has published 19 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Haifaa Abdulhaq's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Haifaa Abdulhaq accept my insurance?

Dr. Haifaa Abdulhaq accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 559-387-1900 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Abdulhaq's expertise for a condition
ConditionClose
    View All 13 Distinguished Conditions
    View All 59 Advanced Conditions
    View All 148 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile